CD200 and neoplasm: All the dogs in this study were treated with a combination of autologous tumor lysate (ATL) and a peptide ligand that interferes with the CD200 immune checkpoint, yet there was a marked disparity in survival time between French bulldogs and boxers and Boston terriers.